| Li, Xiaoming |
NCT06004856: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia |
|
|
| Recruiting | 3 | 195 | RoW | Orelabrutinib, Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Primary Immune Thrombocytopenia (ITP) | 12/25 | 04/26 | | |
TQB3702-II-02, NCT06566586: A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma |
|
|
| Recruiting | 2 | 80 | RoW | TQB3702 tablets+Chemotherapy regimen | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | B-cell Lymphoma | 03/26 | 12/27 | | |
NCT06106841: TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) |
|
|
| Recruiting | 1/2 | 39 | RoW | 400mg of TQB3909 tablets, 600mg of TQB3909 tablets | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Mantle Cell Lymphoma | 12/24 | 12/24 | | |
TQB3909-Ib/II-02, NCT05959694: A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . |
|
|
| Recruiting | 1/2 | 107 | RoW | TQB3909 tablet | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/25 | 06/26 | | |
NCT06521931: A Study of PN20 for the Prevention of Chemotherapy-induced Thrombocytopenia in Lymphoma or Solid Tumor Patients |
|
|
| Recruiting | 1 | 24 | RoW | PN20 | Chongqing Peg-Bio Biopharm Co., Ltd. | Thrombocytopenia | 12/24 | 12/24 | | |
| Recruiting | N/A | 140 | RoW | sham stimulation, intermittent theta-burst stimulation (iTBS) | Second Affiliated Hospital, School of Medicine, Zhejiang University, Shanghai Mental Health Center, The Affiliated Kangning Hospital of Ningbo University, The First Affiliated Hospital of Anhui Medical University | Posttraumatic Stress Disorder | 12/25 | 05/26 | | |
NCT05793502: Study on Effectiveness and Safety of LBBaP With Solia S and Selectra 3D Developed by BIOTRONIK |
|
|
| Recruiting | N/A | 1000 | RoW | Solia S and Selectra 3D Developed by BIOTRONIK | Chinese Academy of Medical Sciences, Fuwai Hospital | Consented to Participate in the Trial and Signed an ICF, Patients With an Indication for PM Implantation or CRTP | 04/25 | 04/25 | | |
NCT05174936: ResIlience-based Stigma REdUction Program ("Rise-up") |
|
|
| Active, not recruiting | N/A | 1928 | US | PLWH intervention, Family member intervention, Healthcare provider intervention | University of South Carolina, Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control | HIV/AIDS, Stigma, Social, Emotional Adjustment | 11/26 | 11/27 | | |
